Author:
Irmer D,Funk J O,Blaukat A
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference83 articles.
1. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H et al. (2005). Aberrant EGFR signalling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226–235.
2. Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H et al. (2005). Enhancement of sensitivity to TNFα in NSCLC cells with acquired resistance to gefitinib. Clin Cancer Res 11: 8872–8879.
3. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K . (2004). Small in-frame deletion in the EGFR as a target for ZD6474. Cancer Res 64: 9101–9104.
4. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H et al. (2006). A phase II trial of gefitinib as first-line therapy for advanced NSCLC with EGFR mutations. Br J Cancer 95: 998–1004.
5. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE . (2004). Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351: 2883.
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献